Literature DB >> 22516068

Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis.

Khadija El Hadri1, Dler Faieeq Darweesh Mahmood, Dominique Couchie, Imene Jguirim-Souissi, Felicitas Genze, Vimala Diderot, Tatiana Syrovets, Oleg Lunov, Thomas Simmet, Mustapha Rouis.   

Abstract

OBJECTIVE: Oxidative stress is believed to play a key role in cardiovascular disorders. Thioredoxin (Trx) is an oxidative stress-limiting protein with anti-inflammatory and antiapoptotic properties. Here, we analyzed whether Trx-1 might exert atheroprotective effects by promoting macrophage differentiation into the M2 anti-inflammatory phenotype. METHODS AND
RESULTS: Trx-1 at 1 μg/mL induced downregulation of p16(INK4a) and significantly promoted the polarization of anti-inflammatory M2 macrophages in macrophages exposed to interleukin (IL)-4 at 15 ng/mL or IL-4/IL-13 (10 ng/mL each) in vitro, as evidenced by the expression of the CD206 and IL-10 markers. In addition, Trx-1 induced downregulation of nuclear translocation of activator protein-1 and Ref-1, and significantly reduced the lipopolysaccharide-induced differentiation of inflammatory M1 macrophages, as indicated by the decreased expression of the M1 cytokines, tumor necrosis factor-α and monocyte chemoattractant protein-1. Consistently, Trx-1 administered to hyperlipoproteinemic ApoE2.Ki mice at 30 μg/30 g body weight challenged either with lipopolysaccharide at 30 μg/30 g body weight or with IL-4 at 500 ng/30 g body weight significantly induced the M2 phenotype while inhibiting differentiation of macrophages into the M1 phenotype in liver and thymus. ApoE2.Ki mice challenged once weekly with lipopolysaccharide for 5 weeks developed severe atherosclerotic lesions enriched with macrophages expressing predominantly M1 over M2 markers. In contrast, however, daily injections of Trx-1 shifted the phenotype pattern of lesional macrophages in these animals to predominantly M2 over M1, and the aortic lesion area was significantly reduced (from 100%±18% to 62.8%±9.8%; n=8; P<0.01). Consistently, Trx-1 colocalized with M2 but not with M1 macrophage markers in human atherosclerotic vessel specimens.
CONCLUSIONS: The ability of Trx-1 to promote differentiation of macrophages into an alternative, anti-inflammatory phenotype may explain its protective effects in cardiovascular diseases. These data provide novel insight into the link between oxidative stress and cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516068     DOI: 10.1161/ATVBAHA.112.249334

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

Review 1.  Nuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart.

Authors:  Philipp Jakobs; Vlad Serbulea; Norbert Leitinger; Anna Eckers; Judith Haendeler
Journal:  Antioxid Redox Signal       Date:  2017-01-18       Impact factor: 8.401

Review 2.  The Oxygen Paradox, the French Paradox, and age-related diseases.

Authors:  Joanna M S Davies; Josiane Cillard; Bertrand Friguet; Enrique Cadenas; Jean Cadet; Rachael Cayce; Andrew Fishmann; David Liao; Anne-Laure Bulteau; Frédéric Derbré; Amélie Rébillard; Steven Burstein; Etienne Hirsch; Robert A Kloner; Michael Jakowec; Giselle Petzinger; Delphine Sauce; Florian Sennlaub; Isabelle Limon; Fulvio Ursini; Matilde Maiorino; Christina Economides; Christian J Pike; Pinchas Cohen; Anne Negre Salvayre; Matthew R Halliday; Adam J Lundquist; Nicolaus A Jakowec; Fatima Mechta-Grigoriou; Mathias Mericskay; Jean Mariani; Zhenlin Li; David Huang; Ellsworth Grant; Henry J Forman; Caleb E Finch; Patrick Y Sun; Laura C D Pomatto; Onnik Agbulut; David Warburton; Christian Neri; Mustapha Rouis; Pierre Cillard; Jacqueline Capeau; Jean Rosenbaum; Kelvin J A Davies
Journal:  Geroscience       Date:  2017-12-21       Impact factor: 7.713

3.  Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease.

Authors:  M Hanief Sofi; Yongxia Wu; Steven D Schutt; Min Dai; Anusara Daenthanasanmak; Jessica Heinrichs Voss; Hung Nguyen; David Bastian; Supinya Iamsawat; Shanmugam Panneer Selvam; Chen Liu; Nilanjana Maulik; Besim Ogretmen; Junfei Jin; Shikhar Mehrotra; Xue-Zhong Yu
Journal:  J Clin Invest       Date:  2019-05-02       Impact factor: 14.808

Review 4.  Redox-Sensitive Innate Immune Pathways During Macrophage Activation in Type 1 Diabetes.

Authors:  Ashley R Burg; Hubert M Tse
Journal:  Antioxid Redox Signal       Date:  2017-11-27       Impact factor: 8.401

Review 5.  The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?

Authors:  Alexey A Tinkov; Geir Bjørklund; Anatoly V Skalny; Arne Holmgren; Margarita G Skalnaya; Salvatore Chirumbolo; Jan Aaseth
Journal:  Cell Mol Life Sci       Date:  2018-01-11       Impact factor: 9.261

Review 6.  Role of Thioredoxin in Age-Related Hypertension.

Authors:  Kumuda C Das; Venkatesh Kundumani-Sridharan; Jaganathan Subramani
Journal:  Curr Hypertens Rep       Date:  2018-02-14       Impact factor: 5.369

Review 7.  Inflammation and atherosclerosis: direct versus indirect mechanisms.

Authors:  Michael E Rosenfeld
Journal:  Curr Opin Pharmacol       Date:  2013-01-26       Impact factor: 5.547

8.  Islet encapsulation with polyphenol coatings decreases pro-inflammatory chemokine synthesis and T cell trafficking.

Authors:  Dana Pham-Hua; Lindsey E Padgett; Bing Xue; Brian Anderson; Michael Zeiger; Jessie M Barra; Maigen Bethea; Chad S Hunter; Veronika Kozlovskaya; Eugenia Kharlampieva; Hubert M Tse
Journal:  Biomaterials       Date:  2017-03-06       Impact factor: 12.479

Review 9.  HIV-associated neuropathogenesis: a systems biology perspective for modeling and therapy.

Authors:  Susanna L Lamers; Gary B Fogel; David J Nolan; Michael S McGrath; Marco Salemi
Journal:  Biosystems       Date:  2014-04-13       Impact factor: 1.973

10.  Loss of NADPH oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes.

Authors:  Lindsey E Padgett; Ashley R Burg; Weiqi Lei; Hubert M Tse
Journal:  Diabetes       Date:  2014-10-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.